Holen Sie sich die Stockscreener-App
0.828
0.24%
-0.002
Windtree Therapeutics Inc Aktie (WINT) Neueste Nachrichten
Windtree Therapeutics Inc. Reports Q1 2025 Financial Results - TipRanks
Windtree Therapeutics (WINT) Registers Up to 42.17M Shares for R - GuruFocus
Windtree Therapeutics (WINT) Plans to Sell Over 42 Million Shares | WINT Stock News - GuruFocus
Windtree Therapeutics Unveils U.S. Exclusivity Strategy for Istaroxime - MSN
Windtree (WINT) Sets Ambitious Plans for Revenue Growth and Rese - GuruFocus
Windtree Therapeutics Reports First Quarter 2025 Financial Resul - GuruFocus
Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates | WINT Stock News - GuruFocus
Windtree Therapeutics Transforms Business Model: New Revenue Strategy, Real Estate Deal, and Clinical Progress - Stock Titan
WINDTREE THERAPEUTICS INC /DE/ SEC 10-Q Report - TradingView
Windtree Therapeutics (WINT) to Release Earnings on Wednesday - Defense World
WINT: Windtree Therapeutics Reveals Promising Data on Istaroxime - GuruFocus
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025 - The Manila Times
Windtree Therapeutics Announces Positive Results on Istaroxime and SERCA2a Activator in Reducing Arrhythmias at ESC Heart Failure Congress - Nasdaq
Windtree Therapeutics Announces Plans to Acquire Multifamily Residential Property - MSN
Warrington-Based Windtree Therapeutics Buys Huston Apartment Complex - BUCKSCO.Today
Daily Progress: Windtree Therapeutics Inc (WINT) Drop -11.76, Closing at 0.90 - DWinneX
Windtree Therapeutics Secures Patent in Japan for Cancer Treatment Platform - MSN
Windtree Therapeutics (WINT) Eyes U.S. Exclusivity for Istaroxime | WINT Stock News - GuruFocus
Windtree Announces Istaroxime Exclusivity and Intellectual Prope - GuruFocus
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US - The Manila Times
Windtree Therapeutics Announces Strategic Pathway for 7.5 Years of U.S. Exclusivity for Istaroxime in Cardiogenic Shock - Nasdaq
Windtree Secures 7.5-Year Exclusivity Strategy for Revolutionary Cardiogenic Shock Treatment - Stock Titan
Why biotech firm Windtree Therapeutics is buying a 436-unit apartment complex - The Business Journals
WINT’s Stock Market Adventure: -94.27% YTD Growth Amidst Volatility - investchronicle.com
Examining Windtree Therapeutics Inc (WINT) more closely is necessary - uspostnews.com
Market Resilience: Windtree Therapeutics Inc (WINT) Finishes Weak at 1.00, Down -14.53 - DWinneX
Windtree Therapeutics (WINT) Pursues Strategic Real Estate Acqui - GuruFocus
Windtree Therapeutics (WINT) Pursues Strategic Real Estate Acquisition | WINT Stock News - GuruFocus
Windtree Therapeutics Raises $2.5M in Private Placement - TipRanks
Windtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline Development - The Manila Times
Windtree Therapeutics Reports 2024 Financial Results and Strategic Developments - MSN
Windtree Therapeutics announces board member resignation By Investing.com - Investing.com Nigeria
Windtree Therapeutics announces board member resignation - Investing.com Australia
Windtree Therapeutics (WINT) Advances Clinical and Strategic Ini - GuruFocus
Windtree Therapeutics Reports 2024 Progress and Strategy Shift - TipRanks
WINDTREE THERAPEUTICS INC /DE/ SEC 10-K Report - TradingView
Windtree Therapeutics reports FY24 EPS ($104.35) vs. ($4,718.84) last year - TipRanks
Windtree Therapeutics sees cash runway through April - TipRanks
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates - TradingView
Company Secures Additional Funding to Sustain Operations Through April 2025 | WINT Stock News - GuruFocus
Windtree Slashes Losses by $18.5M as Cardiogenic Shock Drug Shows Promise - Stock Titan
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Growth in Short Interest - Defense World
Windtree Therapeutics Issues Convertible Notes to Raise $250,000 - Investing.com Australia
Windtree Therapeutics (WINT) to Release Earnings on Tuesday - Defense World
Evofem Biosciences Inks Amendment with Windtree for PHEXXI Supply - Investing.com
Windtree Therapeutics Delays Annual Report Filing - TipRanks
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Decline in Short Interest - Defense World
Windtree Therapeutics Regains Nasdaq Compliance - MSN
Windtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq Compliance - MSN
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):